The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.
 
Lisa Marie Barroilhet
Consulting or Advisory Role - AstraZeneca; Clovis Oncology
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; Boryung; CKD Pharm; Genexine; GI Innovation; Hospicare; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); BeiGene (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Eisai (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); MSD (Inst); OncoQuest (Inst); Pfizer (Inst); Roche (Inst)
 
Sunil Gupta
Employment - CanariaBio; OncoQuest Pharmaceuticals
Leadership - CanariaBio; OncoQuest Pharmaceuticals
Consulting or Advisory Role - CanariaBio
Research Funding - CanariaBio; OncoQuest Pharmaceuticals
Travel, Accommodations, Expenses - OncoQuest Pharmaceuticals
Other Relationship - CanariaBio; OncoQuest Pharmaceuticals
 
Srinivas Rao Jada
No Relationships to Disclose
 
JUNG-YUN LEE
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst)
 
Babak Edraki
Employment - John Muir Medical Group
Stock and Other Ownership Interests - Aspen Surgery Center
Honoraria - AstraZeneca
Consulting or Advisory Role - R-Pharm
 
Casey Cosgrove
Honoraria - GOG Foundation; UpToDate
Consulting or Advisory Role - Agenus; AstraZeneca; GlaxoSmithKline; Imvax; Intuitive Surgical
 
Joyce N. Barlin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; OncoC4
Speakers' Bureau - AstraZeneca; Clovis Oncology; Merck
 
Diane M. Provencher
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Abbvie; AstraZeneca
 
Lukas Rob
Consulting or Advisory Role - Medtronic
 
Devansu Tewari
No Relationships to Disclose
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; Arcus Biosciences; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; InxMed; Jazz Pharmaceuticals; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Takeda; Toray Industries; Umoja Biopharma; VBL Therapeutics; Verastem; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Angeles Alvarez Secord
Honoraria - Myriad Genetics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immutep (Inst); Merck (Inst); OncoQuest Pharmaceuticals (Inst); PharmaMar (Inst); Seagen (Inst); Tesaro (Inst); VBL Therapeutics (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Aravive; GOG Foundation; OncoQuest Pharmaceuticals; Regeneron; Roche/Genentech; VBL Therapeutics